A detailed history of Farrow Financial Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Farrow Financial Inc. holds 19,827 shares of CRSP stock, worth $917,791. This represents 0.59% of its overall portfolio holdings.

Number of Shares
19,827
Previous 17,360 14.21%
Holding current value
$917,791
Previous $938 Million 0.65%
% of portfolio
0.59%
Previous 0.64%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$44.62 - $62.75 $110,077 - $154,804
2,467 Added 14.21%
19,827 $931 Million
Q2 2024

Jul 15, 2024

BUY
$51.17 - $68.18 $17,448 - $23,249
341 Added 2.0%
17,360 $938 Million
Q1 2024

May 02, 2024

SELL
$60.67 - $89.12 $115,333 - $169,417
-1,901 Reduced 10.05%
17,019 $1.16 Billion
Q4 2023

Feb 08, 2024

BUY
$38.62 - $72.18 $730,690 - $1.37 Million
18,920 New
18,920 $1.18 Billion

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.61B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Farrow Financial Inc. Portfolio

Follow Farrow Financial Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farrow Financial Inc., based on Form 13F filings with the SEC.

News

Stay updated on Farrow Financial Inc. with notifications on news.